Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia
{{output}}
B cell prolymphocytic leukemia (B-PLL) is a rare and aggressive disease that is associated with poor survival. Although initially asymptomatic patients do not require therapy, most patients will progress and inevitably require treatment. More than 50% of patie... ...
